Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy.

Autor: Van Nuffel AM; Laboratory of Molecular and Cellular Therapy; Department of Immunology-Physiology; Medical School of the Vrije Universiteit Brussel (VUB); Brussels, Belgium., Wilgenhof S, Thielemans K, Bonehill A
Jazyk: angličtina
Zdroj: Oncoimmunology [Oncoimmunology] 2012 Nov 01; Vol. 1 (8), pp. 1392-1394.
DOI: 10.4161/onci.20926
Abstrakt: A decade of collective work by tumor immunologists has led to improved large scale generation, maturation, antigen loading and administration of dendritic cells (DCs) to cancer patients, promoting enhanced antitumor activity. We alleviated the HLA-restriction in DC therapy and demonstrated that it is meaningful to treat patients with DCs irrespective of their HLA type.
Databáze: MEDLINE